有限公司-logo.jpg "ANKON Technologies 安翰光电技术(武汉)有限公司"){kind=logo}
China
ANKON Technologies is a Chinese high-tech enterprise that successfully developed the world's first precise control digestive tract capsule endoscope robot and achieved commercial application in January 2013. The company has a team of experts with extensive experience in high-tech incubation, including experts from the national "Thousand Talents Program" and outstanding Ph.D. graduates from Silicon Valley.
ANKON Technologies’ NaviCam™ capsule endoscope robot is a powerful tool for early detection of digestive diseases in the stomach and small intestine, improving the early detection rate of gastric cancer and benefiting the public. The platform also holds significant importance in optimizing the allocation of medical resources, evaluating the efficacy of gastrointestinal drug therapy, and evidence-based medical research.
The company's unique technology lies in its proprietary patents for precise magnetic field control and optoelectronic imaging, revolutionary for capsule endoscopes in achieving precise positioning and control, enabling comprehensive and accurate examination of the stomach. With China being a high prevalence area for gastric diseases and having the highest incidence of gastric cancer globally, early detection plays a crucial role in improving the cure rate. The NaviCam™ system offers a new experience for gastric examinations, as it only requires swallowing a capsule endoscope with water, completing a painless, non-invasive, infection-free, and comprehensive stomach examination in about 15 minutes.
Since obtaining the medical device registration certificate from the China National Medical Products Administration in January 2013, the NaviCam™ system has been clinically applied in over ten top domestic hospitals, such as Peking Union Medical College Hospital, General Hospital of Beijing Military Region, and several other hospitals, with positive outcomes. It has also been quickly adopted in prominent professional medical examination centers, garnering wide attention from the general public. Recognized as the most promising seed enterprise in the 2013 Ernst & Young-Fudan China's Most Promising Enterprise Awards, ANKON Technologies has garnered attention from top Chinese leaders and received honors in various high-tech competitions.
Notably, the company secured a $100.00M Venture Round investment on 15 August 2017 from SBCVC, Tongsheng Capital, Youshi Capital, and Dazhong Group, demonstrating confidence from prominent investors in the company’s innovative healthcare technology.
